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Abstract
Human mitochondrial outer membrane protein mitoNEET is a newly discovered target of type II 
diabetes drug pioglitazone. Structurally, mitoNEET is a homodimer with each monomer 
containing an N-terminal transmembrane alpha helix tethered to mitochondrial outer membrane 
and a C-terminal cytosolic domain hosting a redox active [2Fe-2S] cluster. Genetic studies have 
shown that mitoNEET has a central role in regulating energy metabolism in mitochondria. 
However, specific function of mitoNEET remains largely elusive. Here we find that the 
mitoNEET [2Fe-2S] clusters can be efficiently reduced by Escherichia coli thioredoxin reductase 
and glutathione reductase in an NADPH-dependent reaction. Purified human glutathione reductase 
has the same activity as E. coli thioredoxin reductase and glutathione reductase to reduce the 
mitoNEET [2Fe-2S] clusters. However, rat thioredoxin reductase, a human thioredoxin reductase 
homolog that contains selenocysteine in the catalytic center, has very little or no activity to reduce 
the mitoNEET [2Fe-2S] clusters. N-ethylmaleimide, a potent thiol modifier, completely inhibits 
human glutathione reductase to reduce the mitoNEET [2Fe-2S] clusters, indicating that the redox 
active disulfide in the catalytic center of human glutathione reductase may be directly involved in 
reducing the mitoNEET [2Fe-2S] clusters. Additional studies reveal that the reduced mitoNEET 
[2Fe-2S] clusters in mouse heart cell extracts can be reversibly oxidized by hydrogen peroxide 
without disruption of the clusters, suggesting that the mitoNEET [2Fe-2S] clusters may undergo 
redox transition to regulate energy metabolism in mitochondria in response to oxidative signals.
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INTRODUCTION
Thiazolidinediones (TZDs) such as pioglitazone are prescription drugs for patients with type 
II diabetes [1]. While the primary target of TZDs is the peroxisome proliferator-activated 
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receptor γ (PPARγ) which regulates the expression of the genes for fatty acid metabolism 
and insulin signaling pathways [2], TZDs also have the PPARγ-independent physiological 
effects on energy metabolism in mitochondria [3]. This observation led to the discovery of a 
novel mitochondrial outer membrane protein mitoNEET which specifically binds 
pioglitazone [4]. Deletion of mitoNEET in mice decreases the oxidative phosphorylation 
capacity in mitochondria [5]. On the other hand, increased expression of mitoNEET in 
adipocytes enhances lipid uptake and storage and inhibits mitochondrial iron transport into 
the matrix [6], suggesting that mitoNEET may regulate energy metabolism in mitochondria 
[4]. Recent studies further showed that mitoNEET has a central role in development of 
neurodegenerative diseases [7], breast cancer proliferation [8], TNFα-induced necroptosis in 
hepatocytes [9], and browning of white adipose tissue [10], among other pathological 
conditions [11].
Human mitoNEET is a homodimer with each monomer containing an N-terminal 
transmembrane α-helix (residues 14 to 32) tethered to mitochondrial outer membrane [5] 
and a C-terminal cytosolic domain hosting a redox active [2Fe-2S] cluster via the unusual 
ligand arrangement of three cysteine (Cys-72, Cys-74 and Cys-83) and one histidine 
(His-87) residues [12–15]. While the specific function of mitoNEET has not been fully 
understood, several studies have suggested that mitoNEET may transfer its [2Fe-2S] clusters 
to apo-ferredoxin in vitro [16, 17] or to the iron regulatory protein-1 (IRP-1) in vivo [18]. 
Since mitochondria are the primary sites for iron-sulfur cluster biogenesis [19], it was 
compelling to suggest that mitoNEET may act as a carrier transporting iron-sulfur clusters 
assembled in mitochondria to target proteins in cytoplasm [16–18]. Nevertheless, the 
observed cluster transfer occurs only when the mitoNEET [2Fe-2S] clusters are in oxidized 
state [16]. Since the redox midpoint potential of the mitoNEET [2Fe-2S] clusters (Em7) is 0 
mV [20, 21] and the cytosolic redox potential is ~ −325 mV (pH 7.0) [22], the mitoNEET 
[2Fe-2S] clusters are mostly in the reduced state in cells under normal physiological 
conditions [23]. Thus, mitoNEET may transfer its iron-sulfur clusters to target proteins only 
when cells are under oxidative stress conditions [16].
Alternatively, mitoNEET may directly regulate energy metabolism in mitochondria via its 
redox active [2Fe-2S] clusters [20, 23]. It has already been reported that the redox property 
of the mitoNEET [2Fe-2S] clusters can be modulated by pH [21], inter-domain interactions 
[24, 25], hydrogen bond network [26], type II diabetes drug pioglitazone [20], and NADP+/
NADPH [17, 27]. Recent proteomic studies further suggested that mitoNEET may form 
complexes with proteins that are crucial in aging, diabetes, and neurodegenerative diseases 
[28, 29]. Thus, the mitoNEET [2Fe-2S] cluster may act as a sensor of multiple cellular 
signals to regulate mitochondrial functions via specific protein-protein interactions. In 
previous studies, we reported that the mitoNEET [2Fe-2S] clusters are fully reduced when 
expressed in Escherichia coli cells, and that purified mitoNEET [2Fe-2S] clusters can be 
reduced by dithiothreitol or the E. coli thioredoxin/thioredoxin reductase system [23]. 
However, specific components that reduce or oxidize the mitoNEET [2Fe-2S] clusters in 
mammalian cells have not been identified. Here, we find that human mitoNEET [2Fe-2S] 
clusters can be efficiently reduced by E. coli thioredoxin reductase and glutathione reductase 
in an NADPH-dependent reaction. Purified human glutathione reductase [30] has the same 
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activity as E. coli glutathione reductase to reduce the mitoNEET [2Fe-2S] clusters. 
However, rat thioredoxin reductase, a human thioredoxin reductase homolog that contains 
an unusual selenocysteine residue (U498) in the catalytic center [31–33], has very little or no 
activity to reduce the mitoNEET [2Fe-2S] clusters. N-ethylmaleimide, a potent modifier of 
redox active thiols in human glutathione reductase [34], completely inhibits the enzyme to 
reduce the mitoNEET [2Fe-2S] clusters, indicating that the redox active disulfide in the 
catalytic center of human glutathione reductase may be directly involved in reducing the 
mitoNEET [2Fe-2S] clusters. Additional studies show that the reduced mitoNEET [2Fe-2S] 
clusters in the mouse heart cell extracts can be reversibly oxidized by hydrogen peroxide. 
The results led us to propose that the mitoNEET [2Fe-2S] clusters may act as a novel redox 
sensor to modulate energy metabolism in mitochondria in response to oxidative signals.
MATERIALS AND METHODS
1. Protein preparation
A DNA fragment encoding human mitoNEET33–108 (containing amino acid residues 33–
108) was synthesized (Genscript co) and cloned into pET28b+. Recombinant mitoNEET 
was expressed in E. coli BL21/DE3 strain and purified as described previously [23, 35]. E. 
coli thioredoxin reductase [36], glutathione reductase [37], succinic semialdehyde 
dehydrogenase [38], and 2,4-dienoyl-CoA reductase [39] were prepared using the E. coli 
strains from the ASKA library [40]. Recombinant human glutathione reductase was 
prepared using plasmid pUB302 (kindly provided by Professor Katja Becker, Justus Liebig 
University, Germany) in an E. coli strain SG5 (in which gene gor encoding glutathione 
reductase was deleted) [41]. Briefly, E. coli strain SG5 cells hosting pUB302 were grown in 
LB media at 37°C for 5 hours without inducers, harvested, and disrupted by passing through 
French press once. The crude cell extracts were centrifuged at 12,000g for 30 min at 4°C to 
remove cell debris. Supernatant was dialyzed against 20 mM Tris for 5 hours at 4°C. The 
dialyzed sample was added with 1 mM oxidized glutathione (GSSG), and loaded onto an 
ADP-Sepharose column and washed with 0.3 M NaCl. Human glutathione reductase was 
then eluted from the column with 0.8 M NaCl. The purity of purified proteins was greater 
than 95% as judged by electrophoresis analysis on a 15% polyacrylamide gel containing 
SDS followed by staining with Coomassie Blue. The protein concentrations of human 
mitoNEET, E. coli thioredoxin reductase, E. coli glutathione reductase, and human 
glutathione reductase were measured at 280 nm using an extinction coefficient of 8.6 mM−1 
cm−1, 17.7 mM−1 cm−1, 38.2 mM−1 cm−1, and 34.9 mM−1 cm−1, respectively. Native rat 
liver thioredoxin reductase was purchased from Sigma. Recombinant rat thioredoxin 
reductase (containing native selenocysteine in the catalytic center) [42] was purchased from 
Cayman Chemical.
2. Cell extracts preparation from E. coli cells and mouse heart
Wild type E. coli cells (BL21/DE3) were grown in LB media at 37°C under aerobic 
conditions to OD at 600 nm of 1.0. Cells were harvested, washed with buffer containing 
NaCl (500 mM) and Tris (20 mM, pH 8.0), and passed through French press once. After 
centrifugation at 8,000 × g for 30 min at 4°C to remove cell debris, supernatant was loaded 
onto Hi-Trap Desalting column (GE Lifesciences). For the mouse heart cell extracts, hearts 
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from wild-type mice (C57BL/6J, 3–4 weeks old, obtained from the Pennington Biomedical 
Research Center, Louisiana State University) were cleaned in PBS buffer and minced with 
scissors. Heart tissues were ground with a homogenizer and further disrupted by drawing 
and ejecting samples using a syringe with a 26-gauge needle. Cell debris were removed by 
centrifugation at 8,000 × g for 20 min at 4°C, and the supernatant was used for the 
experiments. The protein concentration of the prepared cell extracts was determined using 
Bradford assay [43].
3. Analyses of the redox state of the mitoNEET [2Fe-2S] clusters
Purified human mitoNEET dissolved in buffer containing NaCl (500 mM) and Tris (20 mM, 
pH 8.0) in a sealed vial was purged with pure argon gas for 15 min. The prepared cell 
extracts or enzymes were also purged with pure argon gas before transferred to the sealed 
vials using a gas-tight Hamilton syringe. The reaction solutions were then incubated in a 
37°C water bath for the indicated time before the samples were analyzed by using the 
Beckman DU640 UV-visible spectrometer or EPR (Electron Paramagnetic Resonance). For 
the NEM (N-ethylmaleimide) treatments, purified human glutathione reductase or the mouse 
heart cell extracts were pre-incubated with NEM (2 mM) and NADPH (0.2 mM) at room 
temperature for 30 min to block the redox active monothiols in the proteins.
4. EPR measurements
The X-band EPR (Electron Paramagnetic Resonance) spectra were recorded using a Bruker 
model ESR-300 spectrometer equipped with an Oxford Instruments 910 continuous flow 
cryostat. Routine EPR conditions were: microwave frequency, 9.47 GHz; microwave power, 
10.0 mW; modulation frequency, 100 kHz; modulation amplitude, 1.2 mT; temperature, 30 
K; receive gain, 2×105. The amount of the reduced mitoNEET [2Fe-2S] clusters was 
quantified as in [23].
5. Chemicals
Isopropyl β-D-1-thiogalactopyranoside, NADPH, kanamycin, ampicillin, and dithiothreitol 
were purchased from Research Product International co. Reduced glutathione, oxidized 
glutathione, N-ethylmaleimide, hydrogen peroxide, and other chemicals were purchased 
from Sigma co.
RESULTS
1. Reduction of the mitoNEET [2Fe-2S] clusters by E. coli thioredoxin reductase and 
glutathione reductase
When recombinant human mitoNEET was expressed in E. coli cells, the mitoNEET 
[2Fe-2S] clusters were fully reduced [23], indicating that E. coli cells have a robust activity 
to reduce the mitoNEET [2Fe-2S] clusters. To search for the cellular components that are 
responsible for reducing the human mitoNEET [2Fe-2S] clusters, we prepared cell extracts 
from exponentially growing E. coli cells. Figure 1A shows that while NADPH (spectrum 2) 
or the E. coli cell extracts (spectrum 3) had no activity to reduce the human mitoNEET 
[2Fe-2S] clusters, addition of NADPH to the cell extracts quickly reduced the mitoNEET 
[2Fe-2S] clusters (spectrum 4) which had a typical rhombic EPR (Electron Paramagnetic 
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Resonance) signal at g = 1.94 [12, 23, 26]. The amplitude of the EPR signal at g = 1.94 of 
the mitoNEET [2Fe-2S] clusters in the E. coli cell extracts (spectrum 4) was essentially the 
same as that when the mitoNEET protein was reduced with sodium dithionite (spectrum 5), 
indicating that the mitoNEET [2Fe-2S] clusters are fully reduced in the E. coli cell extracts 
by NADPH.
Since the mitoNEET [2Fe-2S] clusters can be reduced by excess dithiothreitol in vitro [23], 
we reasoned that the mitoNEET [2Fe-2S] clusters may be reduced by reduced thioredoxin 
[23] or the enzymes that contain redox active disulfide in vivo. In E. coli, there are at least 
two reductases: thioredoxin reductase [44] and glutathione reductase [37], that have a redox 
active disulfide in the catalytic center. To test this idea, we prepared E. coli thioredoxin 
reductase and glutathione reductase as described in the Materials and Methods. Purified E. 
coli thioredoxin reductase and glutathione reductase had a similar UV-visible absorption 
spectrum (Figure 1B), indicative of the protein-bound FAD as reported previously [37, 44].
Figure 1C shows that purified E. coli thioredoxin reductase (spectrum 3) or glutathione 
reductase (spectrum 4) had no activity to reduce the mitoNEET [2Fe-2S] clusters. However, 
when mitoNEET was incubated with E. coli thioredoxin reductase and NADPH (spectrum 
5) or E. coli glutathione reductase and NADPH (spectrum 6) at 37°C for 20 min under 
anaerobic conditions, the mitoNEET [2Fe-2S] clusters were fully reduced, suggesting that 
both E. coli thioredoxin reductase and glutathione reductase are able to reduce the 
mitoNEET [2Fe-2S] clusters in the presence of NADPH. In parallel, we also prepared two 
NADPH-dependent reductases: succinic semialdehyde dehydrogenase [38] and 2,4-dienoyl-
CoA reductase [39] from E. coli cells. Both enzymes use NADPH as substrate but do not 
contain the redox active disulfide in the catalytic center. Under the same experimental 
conditions, E. coli succinic semialdehyde dehydrogenase and 2,4-dienoyl-CoA reductase 
had no activity to reduce the mitoNEET [2Fe-2S] clusters in the presence of NADPH (data 
not shown). Thus, E. coli thioredoxin reductase and glutathione reductase have the specific 
activity in reducing the human mitoNEET [2Fe-2S] clusters.
2. Reduction of the mitoNEET [2Fe-2S] clusters by human glutathione reductase
In humans, there are three thioredoxin reductases: a cytosolic form [45], a mitochondrial 
form [46], and a thioredoxin glutathione reductase in the microsomal fraction of testis tissue 
[47]. As mitoNEET localizes on mitochondrial outer membrane [5], it is most likely that 
cytosolic thioredoxin reductase would be responsible for reducing the mitoNEET [2Fe-2S] 
clusters. Like E. coli thioredoxin reductase, human cytosolic thioredoxin reductase contains 
FAD and an NADPH binding site [32, 33, 48]. However, unlike E. coli thioredoxin 
reductase, human thioredoxin reductase has an unusual selenocysteine residue (U498) in the 
catalytic center [31–33]. As native human cytosolic thioredoxin reductase was not readily 
available, we used rat thioredoxin reductase which has 91% identity and 96% similarity to 
human thioredoxin reductase and contains the selenocysteine residue in the catalytic center. 
Rat liver thioredoxin reductase (from Sigma) was fully active to reduce 5,5´-dithiobis-(2-
nitrobenzoic acid). However, unlike E. coli thioredoxin reductase, rat liver thioredoxin 
reductase had very little or no activity to reduce the mitoNEET [2Fe-2S] clusters (data not 
shown). We also obtained recombinant rat thioredoxin reductase (from Cayman Chemical) 
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which also contains the selenocysteine residue and is fully active to reduce 5,5´-dithiobis-(2-
nitrobenzoic acid) (DTNB) [42]. Again, recombinant rat thioredoxin reductase failed to 
reduce the mitoNEET [2Fe-2S] clusters in the presence of NADPH (Figure 2B, spectrum 2).
Human glutathione reductase is a major cellular reductase to reduce the oxidized glutathione 
in cytosol [30, 41]. Unlike human thioredoxin reductase, human glutathione reductase does 
not have selenocysteine in the catalytic center. We thus prepared recombinant human 
glutathione reductase from E. coli cells following the procedures described in [41]. Purified 
human glutathione reductase had a similar UV-visible absorption spectrum as E. coli 
glutathione reductase (Figure 2A), and similar activity to reduce the mitoNEET [2Fe-2S] 
clusters in the presence of NADPH (Figure 2B, spectra 3 and 4). Thus, in human cells, at 
least glutathione reductase is able to reduce the mitoNEET [2Fe-2S] clusters in an NADPH-
dependent reaction.
Pioglitazone, a type II diabetes drug, has been shown to shift the redox midpoint potential 
(Em7) of the mitoNEET [2Fe-2S] clusters by ~ −100 mV [20]. The negative shift of the Em7 
value would make it hard to reduce the mitoNEET [2Fe-2S] clusters. It would be of interest 
to know whether pioglitazone may affect the human glutathione reductase-mediated 
reduction of the mitoNEET [2Fe-2S] clusters. In the experiments, mitoNEET was pre-
incubated with pioglitazone before being reduced with human glutathione reductase and 
NADPH. As shown in Figure 2B, the mitoNEET [2Fe-2S] clusters was only partially 
inhibited (spectrum 5) upon binding of pioglitazone. The result is consistent with the notion 
that binding of pioglitazone to mitoNEET negatively shifts the Em7 of the mitoNEET 
[2Fe-2S] clusters [20, 23] and impedes reduction of the mitoNEET [2Fe-2S] clusters by 
glutathione reductase.
The oxidized mitoNEET [2Fe-2S] clusters have two major UV-visible absorption peaks at 
458 nm and 540 nm [12]. When the mitoNEET [2Fe-2S] clusters are reduced, the absorption 
peak at 458 nm is changed to 420 nm [23]. Here we took advantage of the distinct UV-
visible absorption peaks of the mitoNEET [2Fe-2S] clusters to explore the reduction kinetics 
of the mitoNEET [2Fe-2S] clusters by human glutathione reductase. When mitoNEET was 
incubated with a catalytic amount of human glutathione reductase in the presence of 
NADPH at 37°C under anaerobic conditions, the absorption peak at 458 nm of the oxidized 
mitoNEET [2Fe-2S] clusters was quickly decreased and replaced with the absorption peak at 
420 nm of the reduced mitoNEET [2Fe-2S] clusters (Figure 3A). The amount of the reduced 
mitoNEET [2Fe-2S] clusters in the reaction solution was plotted as a function of incubation 
time. Under the experimental conditions, the mitoNEET [2Fe-2S] clusters were fully 
reduced in 20 min with a half reduction time of less than 5 min (Figure 3B).
3. The redox active disulfide center in human glutathione reductase is involved in reducing 
the mitoNEET [2Fe-2S] clusters
Human glutathione reductase catalyzes the reduction of oxidized glutathione (GSSG) to 
reduced glutathione (GSH) using NADPH as electron donor [30, 41]. If glutathione 
reductase reduces the mitoNEET [2Fe-2S] clusters at the same catalytic site where GSSG is 
reduced, we would expect competition between GSSG and the mitoNEET [2Fe-2S] clusters 
for the catalytic center in the enzyme. To test this idea, we explored the effect of GSSG on 
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the glutathione reductase-mediated reduction of the mitoNEET [2Fe-2S] clusters. Figure 4A 
shows that in the absence of GSSG, the mitoNEET [2FE-2S] clusters (10 µM) were fully 
reduced by 10 µM NADPH in the presence of a catalytic amount of human glutathione 
reductase. In the presence of 10 µM GSSG, however, the mitoNEET [2Fe-2S] clusters were 
reduced only after 20 µM NADPH was added in the incubation solution (Figure 4B). Thus, 
GSSG may effectively block the human glutathione reductase-mediated reduction of the 
mitoNEET [2Fe-2S] clusters by competing for the same catalytic center in the enzyme 
(Figure 4C).
Unlike E. coli thioredoxin reductase and glutathione reductase (Figure 1C) or human 
glutathione reductase (Figure 2B), rat thioredoxin reductase has very little or no activity to 
reduce the mitoNEET [2Fe-2S] clusters (Figure 2B). One possible explanation is that rat 
thioredoxin reductase has an unusual selenocysteine in the catalytic center [31–33], which 
fails to reduce the mitoNEET [2Fe-2S] clusters. If that is the case, we would expect that 
modification of the redox active disulfide in the catalytic center of human glutathione 
reductase may inhibit the enzyme activity to reduce the mitoNEET [2Fe-2S] clusters.
N-ethylmaleimide (NEM), a potent thiol modifier, has been used to inhibit human 
glutathione reductase [34, 49]. Figure 4D shows that the NEM-treated human glutathione 
reductase failed to reduce the mitoNEET [2Fe-2S] clusters (spectrum 2). However, addition 
of sodium dithionite to the above reaction solution quickly restored the EPR signal at g = 
1.94 of the mitoNEET [2Fe-2S] clusters (spectrum 3), suggesting that NEM inhibits human 
glutathione reductase to reduce the mitoNEET [2Fe-2S] clusters without directly modifying 
the mitoNEET [2Fe-2S] clusters. Thus, the redox active disulfide in the catalytic center of 
human glutathione reductase may be directly involved in in reducing the mitoNEET 
[2Fe-2S] clusters.
5. The mitoNEET [2Fe-2S] clusters are fully reduced in the mouse heart cell extracts by 
NADPH
As human glutathione reductase can efficiently reduce the mitoNEET [2Fe-2S] clusters in 
an NADPH-dependent reaction (Figure 3), the mitoNEET [2Fe-2S] clusters may also be 
reduced in mammalian cells by glutathione reductase or similar enzymes. To test this idea, 
we prepared cell extracts from mouse heart as described in the Materials and Methods. 
Figure 5A shows that while the mouse heart cell extracts had no activity to reduce the 
mitoNEET [2Fe-2S] clusters (spectrum 2), addition of NADPH to the cell extracts reduced 
the mitoNEET [2Fe-2S] clusters (spectrum 3) with the EPR amplitude similar to that 
reduced with sodium dithionite (spectrum 4).
The cell extracts were then treated with the thiol modifier NEM to inactivate glutathione 
reductase or similar enzymes. As shown in Figure 5B, the NEM-treated cell extracts had no 
activity to reduce the mitoNEET [2Fe-2S] clusters in the presence of NADPH (spectrum 3). 
Nevertheless, addition of sodium dithionite to the NEM-treated cell extracts immediately 
restored the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters (spectrum 
4), suggesting that NEM inhibits the cellular reductase activities without affecting on the 
mitoNEET [2FE-2S] clusters in the mouse heart cell extracts.
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6. Reduced mitoNEET [2Fe-2S] clusters in the cell extracts are transiently oxidized by 
hydrogen peroxide
To examine whether the mitoNEET [2Fe-2S] clusters may undergo redox transition in 
response to oxidative signals, we treated mouse heart cell extracts containing the pre-
reduced mitoNEET [2Fe-2S] clusters with different amounts of hydrogen peroxide. As the 
concentration of hydrogen peroxide in the cell extracts was increased from 0 to 200 µM, the 
reduced mitoNEET [2Fe-2S] clusters were gradually oxidized (Figure 6A). About 100 µM 
hydrogen peroxide was sufficient to completely oxidize 5 µM mitoNEET [2Fe-2S] clusters 
in the cell extracts (Figure 6B). Importantly, addition of sodium dithionite to the hydrogen 
peroxide-treated cell extracts quickly restored the EPR signal at g = 1.94 of the reduced 
mitoNEET [2Fe-2S] clusters (Figure 6A), suggesting that hydrogen peroxide oxidizes the 
mitoNEET [2Fe-2S] clusters without disrupting the clusters in the protein.
We then asked whether oxidation of the mitoNEET [2Fe-2S] clusters by hydrogen peroxide 
is reversible in the mouse heart cell extracts. In the experiment, the mitoNEET [2Fe-2S] 
clusters oxidized by hydrogen peroxide in the cell extracts with excess NADPH were re-
incubated at 37°C under anaerobic conditions. As shown in Figure 7, the oxidized 
mitoNEET [2Fe-2S] clusters in the cell extracts were almost fully re-reduced after about 30 
min re-incubation.
DISCUSSION
Human mitoNEET is a small mitochondrial outer membrane protein containing a redox 
active [2Fe-2S] cluster. Here we find that the mitoNEET [2Fe-2S] clusters can be efficiently 
reduced by human glutathione reductase in an NADPH-dependent reaction. On the other 
hand, rat thioredoxin reductase, a homolog of human thioredoxin reductase, has very little or 
no activity to reduce the mitoNEET [2Fe-2S] clusters. Oxidized glutathione appears to 
compete for the catalytic site of human glutathione reductase and effectively inhibits the 
enzyme-mediated reduction of the mitoNEET [2Fe-2S] clusters, indicating a potential 
dynamic link between the redox state of the mitoNEET [2Fe-2S] clusters and the ratio of 
oxidized glutathione to reduced glutathione in cells. Additional studies further revealed that 
the reduced mitoNEET [2Fe-2S] clusters in the mouse heart cell extracts can be transiently 
oxidized by hydrogen peroxide without disruption of the clusters in the protein. The results 
suggest that the mitoNEET [2Fe-2S] clusters may undergo redox transition to regulate 
energy metabolism in mitochondria in response to oxidative signals.
The finding that human glutathione reductase [30] can reduce the mitoNEET [2Fe-2S] 
clusters (Figure 2B) is novel. While the underlying mechanism is not immediately clear, it 
seems that the redox active disulfide in the catalytic center of human glutathione reductase 
has a crucial role in reducing the mitoNEET [2Fe-2S] clusters. Both E. coli thioredoxin 
reductase [44] and glutathione reductase [37] contain redox active disulfide in the catalytic 
center and have the same activity to reduce the mitoNEET [2Fe-2S] clusters (Figure 1). In 
contrast, rat thioredoxin reductase, a homolog of human thioredoxin reductase that contains 
an unusual selenocysteine in the catalytic center [31–33], has very little or no activity to 
reduce the mitoNEET [2Fe-2S] clusters (Figure 2B). E. coli succinic semialdehyde 
dehydrogenase [38] and 2,4-dienoyl-CoA reductase [39], which use NADPH as substrate 
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but do not have a redox active disulfide in the catalytic center, also fail to reduce the 
mitoNEET [2Fe-2S] clusters (data not shown). Furthermore, modification of the redox 
active disulfide in human glutathione reductase by thiol modifier NEM [34, 49] completely 
inhibits the enzyme activity to reduce the mitoNEET [2Fe-2S] clusters (Figures 4 and 5). 
Taken together, we conclude that the redox active disulfide in the catalytic center of human 
glutathione reductase may be directly involved in reducing the mitoNEET [2Fe-2S] clusters 
(Figure 8).
While the mechanism for reduction of disulfide by iron-sulfur cluster in proteins has been 
extensively investigated in plant ferredoxin-thioredoxin reductase [50], the reverse reaction 
(reduction of iron-sulfur cluster in proteins by dithiol) is essentially unknown. Interestingly, 
Fridovich’s group previously reported that E. coli thioredoxin reductase may produce 
superoxide by transferring a single electron to dioxygen [51]. Perhaps, E. coli thioredoxin 
reductase utilizes similar mechanism to reduce the mitoNEET [2Fe-2S] clusters (Figure 1C). 
More recently, Buckel’s group showed that butyryl-CoA dehydrogenase from 
Acidaminococcus fermentans, a FAD-containing enzyme, can reduce the ferredoxin 
[4Fe-4S] cluster and crotonyl-CoA simultaneously [52] in a bifurcation reaction [53]. FAD 
acts as an electron gate to deliver one electron at a time for reduction of the ferredoxin 
[4Fe-4S] cluster and crotonyl-CoA in butyryl-CoA dehydrogenase [52]. As human 
glutathione reductase also contains FAD (Figure 2A), we propose that during the reaction 
cycle, an intermediate state of FADH- coupled with the redox active disulfide formed in 
human glutathione reductase [30] may deliver single electrons to reduce the mitoNEET 
[2Fe-2S] clusters (Figure 8).
Under normal physiological conditions, the mitoNEET [2Fe-2S] clusters are mostly in 
reduced state in vivo [23] (Figure 5). However, when cells are under oxidative stress or 
during apoptosis and differentiation, the intracellular redox potential could increase from 
−325 mV (pH 7.0) [22] to as high as +200 mV [54], which would result in oxidation of the 
mitoNEET [2Fe-2S] clusters. The closest distance between two [2Fe-2S] clusters in the 
mitoNEET dimer is about 14 Å [13–15]. Thus, oxidation of the two [2Fe-2S] clusters in the 
mitoNEET dimer may result in confirmation change of the mitoNEET dimer via electric 
repulsion. Since mitoNEET can potentially form protein complexes with E3 ubiquitin ligase 
Parkin [28], V-ATPase [29], tax-responsive enhancer element-binding protein 107 (RPL6) 
[29], translocase of outer mitochondrial membrane 7 homolog (TOMM7) [29], 
mitochondrial outer membrane import complex protein 1 (MTX1) [29], polyubiquitin-C 
(UBC) [55], and glutamate dehydrogenase 1 [56], we postulate that mitoNEET may 
modulate the functions of its binding partners in mitochondria via redox transition of its 
[2Fe-2S] clusters in response to redox signals.
MitoNEET-like proteins are widely distributed in the three domains of life [57–59]. In 
humans, there are two mitoNEET-like proteins: Miner1 [60] and Miner2 [5]. Like 
mitoNEET, the C-terminal domain of Miner1 hosts a redox active [2Fe-2S] cluster via three 
cysteine and one histidine residues [60]. Mutations in Miner1 have been attributed to 
Wolfram Syndrome 2, a disease characterized by juvenile onset diabetes mellitus and optic 
atrophy [61]. Miner1 was initially localized on endoplasmic reticulum [61], but recent 
studies indicated that Miner1 also localizes on mitochondrial outer membrane [62, 63] and 
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has a crucial role in regulating sulfhydryl redox status, the unfold protein response, and Ca2+ 
homeostasis in mitochondria via a yet unknown regulatory mechanism [63]. While the 
physiological function of Miner2 remains unknown, Miner2 is also a mitochondrial outer 
membrane protein [5] hosting two [2Fe-2S] clusters per monomer (unpublished results). It 
may be envisioned that human mitoNEET, Miner1 and Miner2 may modulate different 
functions in mitochondria via redox transition of the [2Fe-2S] clusters.
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Figure 1. The mitoNEET [2Fe-2S] clusters are reduced by E. coli thioredoxin reductase and 
glutathione reductase
A), EPR spectra of the mitoNEET [2Fe-2S] clusters in the E. coli cell extracts. Purified 
mitoNEET (10 µM of [2Fe-2S] clusters) (spectrum 1) was incubated with NADPH (50 µM) 
(spectrum 2), the E. coli cell extracts (4 mg/ml of total protein) (spectrum 3), or NADPH (50 
µM) and the E. coli cell extracts (4 mg/ml of total protein) (spectrum 4) at 37°C for 20 min 
under anaerobic conditions. Spectrum 5, purified mitoNEET (10 µM of [2Fe-2S] clusters) 
reduced with 2 mM sodium dithionite. The EPR signal at g = 1.94 represents the reduced 
mitoNEET [2Fe-2S] clusters. B), purified E. coli thioredoxin reductase and glutathione 
reductase. Spectrum 1, UV-visible absorption spectra of purified E. coli thioredoxin 
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reductase (eTrxB). Spectrum 2, UV-visible absorption spectra of purified glutathione 
reductase (eGor). eTrxB and eGor shown in B) contained about 15 µM of FAD. Insert is a 
photograph of the SDS-PAGE of purified E. coli thioredoxin reductase (lane 1) and 
glutathione reductase (lane 2). C), reduction of the mitoNEET [2Fe-2S] clusters by E. coli 
thioredoxin reductase and glutathione reductase. Purified mitoNEET (10 µM of [2Fe-2S] 
clusters) (spectrum 1) was incubated with NADPH (50 µM) (spectrum 2), E. coli 
thioredoxin reductase (eTrxB) (1 µM) (spectrum 3), E. coli glutathione reductase (eGor) (1 
µM) (spectrum 4), E. coli thioredoxin reductase (1 µM) and NADPH (50 µM) (spectrum 5), 
or E. coli glutathione reductase (1 µM) and NADPH (50 µM) (spectrum 6) at 37°C for 20 
min under anaerobic conditions. The EPR signal at gav = 1.94 represents the reduced 
mitoNEET [2Fe-2S] clusters. The results are the representatives of three independent 
experiments.
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Figure 2. Reduction of the mitoNEET [2Fe-2S] clusters by human glutathione reductase
A), UV-visible absorption spectra of purified E. coli glutathione reductase (eGor) and 
human glutathione reductase (hGSR). Each protein shown in A) contained about 15 µM of 
FAD. B), reduction of the mitoNEET [2Fe-2S] clusters by human cytosolic glutathione 
reductase. A mix of purified mitoNEET (10 µM of [2Fe-2S] clusters) and NADPH (100 µM) 
(spectrum 1) was incubated with rat thioredoxin reductase (0.5 µM) (spectrum 2), E. coli 
glutathione reductase (eGor) (0.5 µM) (spectrum 3), human glutathione reductase (hGSR) 
(0.5 µM) (spectrum 4) at 37°C for 20 min under anaerobic conditions. Spectrum 5, a mix of 
mitoNEET (10 µM of [2Fe-2S] clusters) and NADPH ( 100 µM) was pre-incubated with 
pioglitazone (2.5 mM) at room temperature for 30 min before being reduced with human 
glutathione reductase (0.5 µM). The results are the representatives of three independent 
experiments.
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Figure 3. Reduction kinetics of the mitoNEET [2Fe-2S] clusters by human glutathione reductase 
(hGSR)
A), reduction of (the mitoNEET [2Fe-2S] clusters by human glutathione reductase. Purified 
mitoNEET (10 µM of [2Fe-2S] clusters) was incubated with hGSR (1 µM) and NADPH (20 
µM) at 37°C under anaerobic conditions. Spectra were taken at 0, 2, 5, 10, 20, and 30 min 
after hGSR was added to the reaction solution. The absorption peak at 458 nm represents the 
oxidized mitoNEET [2Fe-2S] clusters, and the peak at 420 nm represents the reduced 
mitoNEET [2Fe-2S] clusters. B), reduction kinetics of the mitoNEET [2Fe-2S] clusters by 
hGSR. The spectra in A) were deconvoluted to the reduced and oxidized mitoNEET 
[2Fe-2S] clusters using KaleidaGraph. The percentage of the oxidized mitoNEET [2Fe-2S] 
clusters was plotted as a function of incubation time. The results are the representatives of 
three independent experiments.
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Figure 4. The redox active disulfide in human glutathione reductase is crucial for reducing the 
mitoNEET [2Fe-2S] clusters
A), reduction of the mitoNEET [2Fe-2S] clusters by human glutathione reductase without 
the oxidized glutathione. Purified mitoNEET (10 µM of [2Fe-2S] clusters) was incubated 
with 0, 5, 10, and 20 µM NADPH and hGSR (0.5 µM) at 37°C for 20 min under anaerobic 
conditions. The samples were subjected to the UV-Visible absorption measurements. B), 
same as in A) except 10 µM GSSG was incubated in each reaction solution. C), effect of 
GSSG on reduction of the mitoNEET [2Fe-2S] clusters. The amount of the reduced 
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mitoNEET [2Fe-2S] clusters was plotted as a function of NADPH in the incubation solution. 
Closed circles, no GSSG. Closed squares, with 10 µM GSSG. D), inhibition of human 
glutathione reductase by NEM (N-ethylmaleimide). Purified hGSR was pre-incubated with 
or without NEM (2 mM) at room temperature for 3 hours. MitoNEET was then incubated 
with NADPH (20 µM) and hGSR (0.5 µM) (spectrum 1) or NADPH (20 µM) and the NEM-
treated hGSR (0.5 µM) (spectrum 2) at 37°C for 20 min under anaerobic conditions. 
Spectrum 3, mitoNEET incubated with the NEM-treated hGSR and NADPH was reduced 
with sodium dithionite (2 mM). The results are the representatives of three independent 
experiments.
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Figure 5. The mitoNEET [2Fe-2S] clusters are reduced in the mouse heart cell extracts by 
NADPH
A), reduction of the mitoNEET [2Fe-2S] clusters in the mouse heart cell extracts. Purified 
mitoNEET (10 µM of [2Fe-2S] clusters) (spectrum 1) was incubated with the mouse heart 
cell extracts (2 mg/ml of total protein) (spectrum 2), or the mouse heart cell extracts 
supplemented with NADPH (100 µM) (spectrum 3) at 37°C for 20 min under anaerobic 
conditions. Spectrum 4, mitoNEET mixed with the mouse heart cell extracts was treated 
with sodium dithionite (2 mM) under anaerobic conditions. Spectrum 5, the mouse heart cell 
extracts were incubated with NADPH without exogenous human mitoNEET. The EPR 
signal at g = 1.94 represents the reduced mitoNEET [2Fe-2S] clusters. B), inhibition of the 
NADPH-mediated reduction of the mitoNEET [2Fe-2S] clusters by N-ethylmaleimide 
(NEM). The mouse heart cell extracts were pre-treated with 0 mM (spectrum 2), and 2 mM 
(spectrum 3) NEM at room temperature for 3 hours. Purified mitoNEET (10 µM [2Fe-2S] 
clusters) mixed with NADPH (100 µM) (spectrum 1) was then incubated with the NEM-
pretreated cell extracts for 20 min at 37°C under anaerobic conditions. Spectrum 4, 
mitoNEET after incubation with the NEM-pretreated cell extracts and NADPH was reduced 
with sodium dithionite (2 mM). The results are the representative of at least three 
independent experiments.
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Figure 6. Hydrogen peroxide-mediated oxidation of the mitoNEET [2Fe-2S] clusters in the cell 
extracts
A), oxidation of the mitoNEET [2Fe-2S] clusters in the cell extracts by H2O2. Purified 
mitoNEET (5 µM of [2Fe-2S] clusters) in the mouse heart cell extracts (1 mg/mL of total 
protein) pre-reduced with NADPH (100 µM) was treated with 0 µM (spectrum 1), 20 µM 
(spectrum 2), 50 µM (spectrum 3), 100 µM (spectrum 4), and 200 µM (spectrum 5) H2O2 for 
5 min. Spectrum 6, the mitoNEET treated with 200 µM H2O2 was immediately reduced with 
sodium dithionite (2 mM). B), titration of hydrogen peroxide in the incubation solution. The 
amplitudes of the EPR signal at g = 1.94 of the reduced mitoNEET [2Fe-2S] clusters were 
plotted as a function of the H2O2 concentration in the cell extracts. The results are the 
representative from three independent experiments.
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Figure 7. Re-reduction of the mitoNEET [2Fe-2S] clusters in the cell extracts after hydrogen 
peroxide exposure
A), re-reduction of the mitoNEET [2Fe-2S] clusters in the cell extracts. Purified mitoNEET 
(5 µM of [2Fe-2S] clusters) was incubated with NADPH (2 mM) and the mouse heart cell 
extracts (1 mg/mL of total protein) at 37°C for 15 min under anaerobic conditions (spectrum 
1). The pre-reduced mitoNEET [2Fe-2S] clusters in the cell extracts were treated with 100 
µM hydrogen peroxide for 5 min (spectrum 2), and re-incubated at 37°C under anaerobic 
conditions for 10 min (spectrum 3), 20 min (spectrum 4), and 30 min (spectrum 5). B), time 
course of re-reduction of the mitoNEET [2Fe-2S] clusters in the cell extracts by NADPH 
after the hydrogen peroxide treatment. The amplitudes of the EPR signal at g = 1.94 were 
plotted as a function of time after addition of H2O2 to the incubation solution. The tesults 
are the representatives of three independent experiments.
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Figure 8. A proposed model for redox transition of the mitoNEET [2Fe-2S] clusters in response 
to hydrogen peroxide in mammalian cells
Cytosolic reductases (e.g. glutathione reductase) transfer electrons from NADPH to FAD to 
form FADH− which in turn transfers single electron to reduce the mitoNEET [2Fe-2S] 
clusters. When cells are subjected to oxidative stress, the reduced mitoNEET [2Fe-2S] 
clusters are reversibly oxidized by hydrogen peroxide.
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